Stay updated on Nivolumab Ibrutinib in CLL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.

Latest updates to the Nivolumab Ibrutinib in CLL Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe change is a minor version update (v3.4.2 replacing v3.4.1) and does not affect study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedA new page revision, v3.4.1, was added and the previous revision v3.4.0 was removed; this appears to be a backend/UI version update rather than a change to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedAdded a glossary toggle and site revision information (v3.4.0) along with the updated 'Last Update Submitted that Met QC Criteria' label. The previous wording 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and revision 'v3.3.4' were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page. There are no visible changes to the study details or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a dedicated Locations section with Texas as a study site. The previous Texas Locations entry was removed and the page revision updated to v3.3.3 (HHS Vulnerability Disclosure link removed).SummaryDifference0.2%

- Check92 days agoChange DetectedThe Publications section now displays auto-filled PubMed notes and includes a new revision label (v3.3.2). The older PubMed-source description was removed and replaced with the updated revision tag (v3.2.0).SummaryDifference0.1%

Stay in the know with updates to Nivolumab Ibrutinib in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.